Autofluorescence Tracking of Somatic Cell Reprogramming

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for biomanufacturing patient-specific induced pluripotent stem cells (iPSCs) are not integration-free, efficient, scalable, or easily transferrable to Good Manufacturing Practice (GMP)-compliant conditions, limiting their application in disease modeling, drug discovery, and personalized therapies.

Innovation Solution

A somatic cell reprogramming tracking device that includes a cell analysis observation zone, an autofluorescence spectrometer, and a processor, which uses autofluorescence data to predict the reprogramming status of cells based on metabolic and nuclear parameters, enabling the physical isolation of cells and generation of pseudotime reprogramming pathway maps for improved tracking and prediction.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current methods for biomanufacturing iPSCs are used, then cell reprogramming can be achieved, but the process is not integration-free, scalable, or easily transferrable to GMP-compliant conditions

Engineering Contradiction:

ImproveGMP complianceVSAvoidbiomanufacturing process complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent replaces complex mechanical and manual tracking methods with an optical detection system that uses autofluorescence spectroscopy to monitor reprogramming intermediates. This substitution enables automated, non-invasive tracking that is compatible with GMP-compliant biomanufacturing processes, resolving the contradiction between reliability and device complexity.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Productivity

If traditional cell tracking methods are used, then reprogramming status can be monitored, but the methods are not efficient or scalable

Engineering Contradiction:

Improvereprogramming tracking efficiencyVSAvoidtracking time

Core Design Contradiction:

ProductivityVSLoss of time

Solution Approach 1:

The patent implements continuous monitoring of reprogramming intermediates through real-time autofluorescence detection. The system continuously tracks metabolic changes without interrupting the reprogramming process, enabling efficient and scalable monitoring that eliminates time losses associated with discrete sampling and analysis methods.

Inventive Principle:

Principle #20Continuity of useful action

Solution Approach 2:

The system utilizes the cell's own autofluorescence properties as a natural tracer for tracking reprogramming status. By detecting endogenous metabolic changes without requiring external labels or interventions, the method achieves efficient tracking while minimizing time loss and maintaining scalability.

Inventive Principle:

Principle #25Self-service

3Loss of information

If autofluorescence spectroscopy is used for tracking, then label-free monitoring is achieved, but measurement precision requirements increase

Engineering Contradiction:

Improvelabel-free tracking capabilityVSAvoidautofluorescence measurement precision

Core Design Contradiction:

Loss of informationVSMeasurement precision

Solution Approach 1:

The patent monitors dynamic changes in autofluorescence parameters (intensity, spectral shape, lifetime) that occur during reprogramming. By tracking multiple parameters simultaneously and analyzing their temporal evolution, the system achieves label-free tracking with sufficient measurement precision to distinguish reprogramming stages without requiring extreme precision from any single measurement.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for accurate classification of somatic cell reprogramming status with high accuracy, efficient isolation of induced pluripotent stem cells, and prediction of future reprogramming outcomes, facilitating scalable and GMP-compliant biomanufacturing of iPSCs.

Implementation Method 1

The autofluorescence spectrometer is configured to acquire an autofluorescence data set for the reprogramming intermediate cell located in the cell analysis observation zone

Methodology Applied

Scientific EffectAutofluorescence: Fluorescence

Data Source

PatentUS20230123017A1Systems and methods for label-free tracking of human somatic cell reprogramming

Publication Date: 2023.04.20 WISCONSIN ALUMNI RES FOUND

AI summary

Systems and methods for identifying a current reprogramming status and for predicting a future reprogramming status for reprogramming intermediate cells (i.e., somatic cells undergoing reprogramming) are provided. Label-free autofluorescence measurements are combined with machine learning techniques to provide highly accurate identification of current reprogramming status and prediction of future reprogramming status. The identification of current reprogramming status utilizes metabolic endpoints from the autofluorescence data set. The prediction of future reprogramming status utilizes a pseudotime line constructed from autofluorescence data of reprogramming intermediate cells having a known reprogramming status.